A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202) - Concepedia

Concepedia

Publication | Open Access

A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202)

DOI Full Paper Access

69

Citations

38

References

2022

Year

Sheela Rao, Gayathri Anandappa, Jaume Capdevila, Laëtitia Dahan, Ludovic Evesque, Stéfano Kim, Mark Saunders, Duncan C. Gilbert, Lars Henrik Jensen, Emmanuelle Samalin,

Abstract

Retifanlimab demonstrated clinically meaningful and durable antitumor activity, and an acceptable safety profile in patients with previously treated locally advanced or metastatic SCAC who have progressed on or are intolerant to platinum-based chemotherapy.

References

	Year	Citations

Page 1